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Methods

Approximately, 200,000 Americans under the age of 65 are
suffering from Alzheimer disease today and, unfortunately,
there is currently no cure. Researchers believe that the cause
of Alzheimer's disease is mostly due to the aggregation of
Amyloid-β (Aβ) peptide.1 Generally, the aggregation of Aβ
is initiated and enhanced when the balance between oxidants
and antioxidants is disrupted in the brain.2 This unbalancing
process between antioxidant and oxidant is called oxidative
stress. Oxidative stress can occur when there is an increase in
free radical concentrations within the brain. Research studies
indicated that the major source of free radicals in our brain is
due to the reduction of molecular oxygen in water. It has
been proven that oxygen gas is reduced into superoxide
radical, which further reduced into hydrogen peroxide.
Hydrogen peroxide is then subsequently reduced into a
highly reactive hydroxyl radicals,2 this reactive oxygen
species (ROS) can disrupt lipids membranes, proteins,
nucleic acids,3 via a chain of irreversible oxidative reactions.
Thus, our interest is to develop drugs and/or methods for (1)
quenching/trapping excess produced hydroxyl radicals into
non-toxic products and (2) stopping or slowing down the
formation of aggregation of amyloid β (Aβ) peptide.
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2. Optimization of [DHN] concentration for hydroxyl radical
quenching reactions.
3. DHN, TMPyP, and Juglone effect on Amyloid-β
aggregation
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4. Study hydroxyl radical effects on Amyloid-β aggregation
using TMPyP, DHN, and Fenton reagents.

Results

3. DHN, TMPyP, and Juglone effect on Amyloid-β
aggregation observed by UV-Vis spectroscopy
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Figure 2: Absorption spectra of DHN (301 nm) in the
presence of amyloid-β. (a) 1 x 10-5 M DHN and (b) DHN
with 8 μM amyloid-β over time. Spectra was recorded every
10 minutes for an hour.
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Figure 3: Absorption spectra of TMPyP (423 nm) in the
presence of amyloid-β. Spectra was recorded every 10
minutes for an hour. (a) 8 μM amyloid-β (b) 6 μM TMPyP (c)
TMPyP and Aβ at 0 mins (d) TMPyP and Aβ at 60 mins.

1

(b)

0.8

0.03
(b)

0.7

0.025

0.6
0.5
0.4

0.3
0.2

(a)

0.1
0
0

5

10

15

20

25

30

35

520

570

Figure 5: Absorption spectra of DHN (301 nm) and TMPyP
(423 nm) in the presence of amyloid-β and Fenton reaction.
(a) 1.4 x 10-4 M DHN, 6 μM TMPyP and 8 μM amyloid-β (b)
DHN, TMPyP, Aβ and 3 mM Fe(II) (c) DHN, TMPyP, Aβ
with Fenton Reaction recorded over time. Spectra was
recorded every 10 minutes for an hour.

• The absorption spectra revealed that DHN successfully
intercalated into the peptide chains and can prevent or slow
down amyloid-β aggregate formation. Synergistic effect
observed upon addition of TMPyP with DHN.
• Figure 5 shows a relatively slow decrease and right shift in
the TMPyP peak at 423 nm. This is indicative of a TMPyP
and Aβ aggregation interaction. However, in the presence
of DHN, the absorption spectra of TMPyP decreases
indicating TMPyP is selectively reacting with hydroxyl
radicals. Further investigation is need to understand what is
occurring during the reaction.

Future Work
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2. Optimization of [DHN] for determining the slowest rate in
which methylene blue is oxidized
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Figure 1: A comparison of absorption spectra of methylene
blue at 664 nm in the presence of (a) reactive oxygen species
and (b) reactive oxygen species and DHN.
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• The oxidation of methylene blue (3.1 x 10-3 s-1) was
drastically reduced in the presence of DHN (3.0 x 10-4 s-1).
These results suggest that DHN could be a possible option
for slowing the rate of amyloid-β aggregation.

0.02

0.9

370

Conclusion

(c)

0.1

0.04

1. Quenching of hydroxyl radical generated in situ via Fenton
reaction where DHN and methylene blue (MB) are used as
hydroxyl radical quenchers.
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Introduction

1. Quenching of hydroxyl radical generated in situ via
Fenton reaction where DHN and methylene blue are used
as hydroxyl radical quenchers.

A/AO

Alzheimer disease (AD) is recognized as the six leading
cause of the death in the United States. As of now, there is
no cure for this fatal disease. The current treatment methods
can only temporarily slow the worsening of symptoms.
Research data suggested that an excess generation of
hydroxyl radical in the brain causing the aggregation
of Amyloid-β (Aβ) peptide which is considered to be
responsible for Alzheimer's disease. Thus, there is a pressing
need to find a suitable drug which can quench hydroxyl
radicals effectively and stop or slow down the formation of
aggregation of Aβ peptide. The primary objective of the
project is to find out a dual functional drug which can quench
the reactive hydroxyl radicals produced in the brain and
prevent Aβ peptide chains to come close to form Aβ peptide
aggregate at the same time. A small organic molecule 1,5dihydroxynapthalene (DHN) was found to quench hydroxyl
radical at a rate of 3 X 10-4 s-1. An independent experiment
suggested that it intercalated efficiently into the Aβ peptide
chains. Upon addition of meso-tetra(N-methyl-4pyridyl)porphyrin tetrachloride (TMPyP) with DHN, a strong
synergistic effect in quenching the hydroxyl radical and
intercalating into the Aβ peptide chains was observed. This
data suggests that DHN or DHN & TMPyP are the potential
drug for Alzheimer disease treatment.
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Figure 4: Absorption spectra of Juglone (429 nm) in the
presence of amyloid-β. (a) 5 x 10-5 M Juglone and (b) Juglone
with 8 μM amyloid-β over time. Spectra was recorded every
10 minutes for an hour.
4. Hydroxy radical effects on Amyloid-β aggregation
observed using UV-visible spectroscopy and TMPyP

• Analyze atomic force microscopy imaging of Amyloid-β
aggregates in the presence of DHN.
• Assessment of conformational changed in the presence of
TMPyP and DHN by circular dichroism spectroscopy.
• Observer biomolecule interactions using surface plasmon
resonance.
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